Results From a Phase 2, Open‐Label Study Evaluating the Safety, Tolerability, and Effect on Ataxia of GLM101 in Three Adult Patients With PMM2‐CDG
Mercedes Serrano, Florencia Epifani, Rose Marino, Peter McWilliams · 2026
Read Results From a Phase 2, Open‐Label Study Evaluating the Safety, Tolerability, and Effect on Ataxia of GLM101 in Three Adult Patients With PMM2‐CDG by Mercedes Serrano, Florencia Epifani, Rose Marino, Peter McWilliams (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13548179.txt.
Description
Mercedes Serrano and three colleagues report the first treatment results for a new enzyme-replacement drug in three adults with PMM2-CDG, a rare inherited glycosylation disorder. The disease cripples a sugar-handling step and produces a prominent balance disorder, ataxia, scored on a standard rating scale. The drug delivers the missing middle molecule in liposomes.
Weekly infusions for twenty-four weeks were well tolerated, with no serious adverse events. Ataxia scores improved clearly by week twelve and further by week twenty-four, across all scale subdomains, and both patients and clinicians reported global gains. With only three patients the authors urge caution, but the signal supports continued trials.
Catalog record
| CREATOR | Mercedes Serrano, Florencia Epifani, Rose Marino, Peter McWilliams |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |